January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
NICE Rejects Another Cancer Drug, Stresses Low Cost-Effectiveness
March 2nd 2016Imbruvica, developed by Janssen for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who are unsuitable to receive chemo-immunotherapy, has been rejected by UK’s National Institute of Health and Care Excellence.
Read More
Alzheimer's Disease Costs Disproportionately Affect Women
September 16th 2015Women bear greater costs related to Alzheimer's disease (AD) compared with men for 2 reasons: they are at greater risk of developing the AD and cost Medicare and Medicaid more, and they are more likely to provide informal, unpaid care to family members with AD.
Read More
Misdiagnosis of Alzheimer's Disease Is Costly for Patients
August 3rd 2015The diagnosis and management of patients with dementing illnesses can be challenging, but the cost of misdiagnosing dementia as Alzheimer's disease can be as high as $14,000 a year, according to a study published in Alzheimer's & Dementia.
Read More
Patients With Alzheimer's Disease Will Consume a Quarter of Medicare's Spending
July 22nd 2015By 2050 more than 28 million additional baby boomers will develop Alzheimer's disease and the cost of caring for them will account for nearly one-fourth of Medicare spending by 2040, according to research presented at the Alzheimer's Association International Conference.
Read More
Speedy Drug Approvals Have Become the Rule, Not the Exception
May 2nd 2015A majority of recent drug development has been in therapies that qualify for at least one special approval pathway that Congress has passed over the past few decades for important drugs that treat life-threatening or rare diseases.
Read More
Biogen's Alzheimer's Drug Sharply Slows Cognitive Decline
March 21st 2015An experimental drug for Alzheimer's disease sharply slowed the decline in mental function in a small clinical trial, researchers reported Friday, reviving hopes for an approach to therapy that until now has experienced repeated failures.
Read More
ASCO Declares CLL Regimens Cancer
January 20th 2015In it's report, "Clinical Cancer Advances 2015: ASCO's Annual Report on Progress Against Cancer," published in the Journal of Clinical Oncology, 4 newly approved treatments for CLL were predicted to have a dramatic impact on patients with the disease.
Read More
SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CML
December 9th 2014Results from a large phase 3 prospective randomized open-label trial, comparing imatinib 400 mg with dasatinib 100 mg daily, were presented by Stephen O'Brien, MD, professor of hematology, Newcastle University Medical School, Newcastle upon Tyne, England.
Read More
Evaluating Safety, Efficacy, and Outcomes of TKIs in CML
December 8th 2014A poster session on the second day of the 56th annual meeting of the American Society of Hematology, held December 6-9, San Francisco, was dedicated to trials evaluating therapeutic options in chronic myelogenous leukemia. Data presented included safety, efficacy, managing comorbidities, and biological differences that drive response to therapy.
Read More
TKIs and Molecular Response in CML: the EURO-SKI Study
December 8th 2014On the second day at the Annual Meeting of the American Society of Hematology 2014, Francois-Xavier Mahon, MD, PhD, Bordeaux Hospital, INSERM 1035, Bordeaux, France, shared the results from the European LeukemiaNet Stop TKI (EURO-SKI) study; the trial used tyrosine kinase inhibitors (TKIs) in CML to define prognostic markers to increase the rate of patients in durable deep molecular response after stopping TKI.
Read More
US Hospitals Wary of Caring for Ebola Patients Because of Cost and Stigma
November 30th 2014US officials trying to set up a network of hospitals in this country to care for Ebola patients are running into reluctance from facilities worried about steep costs, unwanted attention, and the possibility of scaring away other patients.
Read More
Officials Revise Goals on Containing Ebola After Signs of Wider Exposure in Mali
November 23rd 2014The leaders of the United Nations and the World Health Organization expressed renewed alarm on Friday about Ebola's tenacity in Africa and, in particular, its potential to ravage a fourth country, Mali, where they said hundreds of people had been exposed to an infected cleric who died last month.
Read More
Hospitals' Struggles to Beat Back Familiar Infections Began Before Ebola Arrived
October 23rd 2014While Ebola stokes public anxiety, more than 1 in six hospitals-including some top medical centers-are having trouble stamping out less exotic but sometimes deadly infections, federal records show.
Read More
Report of Second Texas Nurse With Ebola Fans Hospital Safety Fears
October 15th 2014Health officials from CDC and the state of Texas are reeling in the wake of today's report that a second nurse at the Texas hospital that treated Ebola patient Thomas Eric Duncan has tested positive for the virus. The news came while health leaders were still trying to determine how 26-year-old nurse Nina Pham contracted Ebola while caring for the first patient diagnosed with the disease on US soil. Meanwhile, the largest nurses' union says its members report that most hospitals are not ready for an Ebola patient.
Read More